Research Article: Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L) Inhibitors and Molecular Targeted Therapy
Abstract:
Liver cancer is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The most common type is HCC, accounting for approximately –% of cases, with a five-year survival rate of only about %. Due to its insidious onset, over % of patients are diagnosed at an advanced stage, making surgical resection or ablation for curative intent no longer feasible.
Introduction:
Liver cancer is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The most common type is HCC, accounting for approximately –% of cases, with a five-year survival rate of only about %. Due to its insidious onset, over % of patients are diagnosed at an advanced stage, making surgical resection or ablation for curative intent no longer feasible.
Read more